An interventional study of Dot-Probe Attention Bias Modification (ABM) and Placebo Training in Social Anxiety Disorder (SAD), Attention Bias Modification Treatment (ABMT) and Placebo Effect, sponsored by Tel Aviv University. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Tel Aviv University · Not applicable, Interventional, and Treatment
This study examines whether a computerized attention-training intervention called attention bias modification (ABM) can reduce symptoms of social anxiety disorder (SAD) in adults, and whether symptom improvement is specifically related to changes in attentional processing or to nonspecific factors such as expectancy and placebo effects.
This study examines whether a computerized attention-training intervention called attention bias modification (ABM) can reduce symptoms of social anxiety disorder (SAD) in adults, and whether symptom improvement is specifically related to changes in attentional processing or to nonspecific factors such as expectancy and placebo effects.
Social Anxiety Disorder is characterized by persistent fear of social situations and negative evaluation by others. Previous research suggests that individuals with SAD tend to direct their attention toward socially threatening information, such as angry facial expressions. ABM was developed to reduce these attentional biases by training individuals to shift attention away from threat-related stimuli. However, findings regarding the clinical efficacy of ABM have been mixed, and some studies suggest that symptom improvement may also result from placebo-related factors, including treatment expectancy and engagement with the intervention.
In this randomized controlled trial, 90 adults diagnosed with Social Anxiety Disorder will be assigned to one of three study conditions: (1) active dot-probe ABM training, (2) placebo computerized training, or (3) a wait-list control group. Participants in the active and placebo training groups will complete eight computerized training sessions over four weeks.
The study will assess changes in social anxiety symptoms before and after the intervention using clinical interviews, self-report questionnaires, and computerized attention tasks. In addition, the study will examine attention bias and attention bias variability (ABV), using both reaction-time-based and eye-tracking-based measures, to better understand changes in attentional processing over time. Treatment expectancy and perceived credibility of the intervention will also be evaluated.
The hypothesis is that participants receiving active ABM training and placebo training will show greater reductions in social anxiety symptoms compared to the wait-list control group, and that participants in the active condition will show greater reduction in symptoms than the placebo condition. The study further hypothesizes that only the active ABM condition will produce significant changes in attention bias and attentional bias variability. Overall, the study aims to clarify the specific and nonspecific mechanisms underlying symptom improvement following Attention Bias Modification interventions for Social Anxiety Disorder.
Exclusion Criteria:
Mechanized Dot-Probe Attention Bias Modification (ABM) training attention away from threat faces. Participants identify the direction of an arrowehead presented at the location of neutral faces.
Behavioral: Dot-Probe Attention Bias Modification (ABM)
Mechanized Intervention: Placebo Training, presenting a single, centered, non-face oval shape in each trial. Participants identify the direction of an arrowehead centrally presented.
Behavioral: Placebo Training
No Intervention / Wait-List, assessments at the same intervals as the active and placebo conditions without intervention in between.
Participants complete a computerized dot-probe attention training task designed to train attention away from threat-related stimuli. During each trial, angry and neutral facial expressions are presented simultaneously, followed by a probe that consistently appears in the location of the neutral face. Participants complete eight training sessions over four weeks.
Also known as: ABM
Participants complete a computerized task matched to the active training condition in duration, structure, and task demands, but without exposure to emotional stimuli or attentional training contingencies. The task is designed to control for nonspecific factors such as expectancy and engagement. Participants complete eight sessions over four weeks.
Change in social anxiety symptoms
Change in social anxiety symptom severity from baseline to post-intervention as measured by the Liebowitz Social Anxiety Scale (LSAS). Min-Max values 0-80, higher scores mean worse outcome.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Change in reaction-time-based attention bias measured in miliseconds
Change in attention bias derived from reaction-time performance on the dot-probe task.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Change in reaction-time-based attention bias variability
Change in attention bias variability derived from reaction-time performance on the dot-probe task.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Change in eye-tracking-based attention bias
Change in attention bias measured using eye-tracking during a free-viewing task with threat-related and neutral facial stimuli.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Change in eye-tracking-based attention bias variability
Change in attention bias variability measured using eye-tracking during a free-viewing task with threat-related and neutral facial stimuli.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Treatment Expectancy and Credibility
Participant-rated treatment expectancy and perceived credibility assessed using the Credibility/Expectancy Questionnaire (CEQ). 0-9 scale and 0% - 100%. Higher scores indicate greater treatment credibility and greater expectation of improvement.
Time frame: Baseline one-week before treatment begins
Change in depressive symptoms
Change in depressive symptom severity measured using the Patient Health Questionnaire-9 (PHQ-9). Scale range 0-20, higher scores mean worse outcome.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Change in Generalized Anxiety Symptoms
Change in generalized anxiety symptoms measured using the Generalized Anxiety Disorder-7 scale (GAD-7). Scores range 0-21, higher scores mean worse outcome.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Self report change in social anxiety symptoms
Change insocial anxiety symptom severity measured using the Social Phobia Inventory (SPIN). Scores range 0-68, higher scores mean worse outcome.
Time frame: a) Baseline one-week before treatment begins; b) an average of 2 weeks following treatment completion. Total time frame (baseline-post) an average of 6 weeks.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tel Aviv University